Crinetics Pharmaceuticals (FRA:6Z4) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6Z4 Crinetics Pharmaceuticals Inc FRA:6Z4
35 GF Score
Price €71.34
GF Value €708.97
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Crinetics Pharmaceuticals Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Crinetics Pharmaceuticals Quality Rank Related Terms

FRA:6Z4
35GF Score
Crinetics Pharmaceuticals Inc FRA:6Z4
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Crinetics Pharmaceuticals (FRA:6Z4) Overvalued in 2026?

Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued. The current stock price of €71.34 is trading 89.9% below its estimated GF Value™ of €708.97. GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:6Z4:

  • Quality Rank:
  • GF Value™: €708.97 vs. price of €71.34 (89.9% below fair value)
  • GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the FRA:6Z4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Crinetics Pharmaceuticals Business Description

Other Exchanges CRNX:USA
Address 6055 Lusk Boulevard, San Diego, CA, USA, 92121
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
35GF Score

Get the complete analysis for FRA:6Z4

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€71.34
Price
€708.97
GF Value